Nemolizumab Sustains Atopic Dermatitis Control Through 3 Years
Long-term data show nemolizumab maintained skin clearance and itch control in atopic dermatitis patients through 3 years of continuous therapy, reinforcing its durability profile.
Topic
Biologic Therapy
Topic
Biologic Therapy
Lebrikizumab Shows Benefit in Pediatric Atopic Dermatitis Via Selective IL-13 Blockade
Selective IL-13 inhibition with lebrikizumab showed benefit in pediatric atopic dermatitis, per a new medical reference summary f…
Real-World Data Support Long-Term Dupilumab Use in Pediatric Atopic Dermatitis
Real-world evidence supports long-term dupilumab use in children with atopic dermatitis, AJMC reports, strengthening payer and cl…